Pyrotinib not checked

Hengrui · SHR1258

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
13 in total
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane, Breast Cancer
Main trialPhase 3
“The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.”In the company’s words, NCT05424835 on ClinicalTrials.gov
Other names
SHR1258 · Irene · BLTN

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 Dec 2026 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Phase 3Active, not recruiting Jun 2027 A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Phase 3Unknown 30 Dec 2022 A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Phase 3Completed 2 Jun 2023 Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Phase 3Unknown Jun 2023 A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Phase 3Completed 31 Jan 2024 Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Phase 2Completed 20 Jun 2019 A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Phase 2Withdrawn 5 Jun 2025 A Trial of SHR1258 in Patients With Biliary Tract Cancer
Phase 1Completed 30 Apr 2020 A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
Phase 1Unknown 28 Jan 2021 Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
Phase 1Unknown May 2021 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Phase 1Completed 2 Aug 2022 Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Phase 1Completed 10 Aug 2022 Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pyrotinib

Following is part of Solo: you see every change to Pyrotinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in